TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01643226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL System
Description: 30 mW/cm2
Study: NCT03033719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Open surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Minimally invasive surgery
Study: NCT06490575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults
Description: Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
Study: NCT04631887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress: An Illustrated Guide
Description: The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises.
Study: NCT03212794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery coach
Description: The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
Study: NCT02032069

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study: NCT03440424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: oral tablet
Study: NCT03570450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived Stem Cell
Description: 4 doses
Study: NCT03799783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
Study: NCT02569866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Capsules containing cephalexin/500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing placebo/500mg
Study: NCT03921255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Bias Modification
Description: There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
Study: NCT01827059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: 125-mg orange-white, round, biconvex, film-coated tablets
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study: NCT00866203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDS vs ProMECE/CytaBOM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDS vs ProMECE/CytaBOM
Study: NCT01843101

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Imaging of the cornea using ultrahigh resolution Spectral Domain OCT

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01827059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04054349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
Study: NCT03282708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh stool collection
Description: One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire
Study: NCT01843101

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
Study: NCT03276871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telescopic Dissection
Description: Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02063256

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 7 nuts a day
Description: add 7 nuts a day (whole shelled weight 75 grams) to standard diet
Study: NCT00296725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
Study: NCT03570450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived Stem Cell
Description: 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived Stem Cell
Description: 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived Stem Cell
Description: 4 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01534078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin, vinblastine, and dacarbazine
Description: Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
Study: NCT03336242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT00742599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-11
Description: 20 ml NPO-11

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml NPO-11(Placebo)
Study: NCT04133246

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus group
Description: Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual interview
Description: Interview led by the psychologist about the patient's parenthood
Study: NCT00792519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV support group
Description: group support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: group cognitive behavioral treatment
Study: NCT03276871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Dissection
Description: Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
Study: NCT01803555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol SPIROMAX®
Description: BF Spiromax will be administered per dose and schedule specified in the arm.
Study: NCT02063256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
Study: NCT03916146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training Intervention
Description: Adapted version of the Family Check-Up/Everyday Parenting intervention
Study: NCT04201535

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein arrays on plasma samples
Description: Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein arrays on plasma samples
Description: Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein arrays on plasma samples
Description: Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
Study: NCT01786122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Physical activity
Description: Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
Study: NCT01803555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYMBICORT® TURBOHALER®
Description: Symbicort Turbohaler will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYMBICORT placebo
Description: SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPIROMAX Placebo
Description: SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
Study: NCT03995498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre
Description: Glucose levels will be measured by the FreeStyle Libre
Study: NCT01786122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education program on healthy habits
Description: education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
Study: NCT00296725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
Study: NCT03995498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre
Description: Glucose levels will be measured by the FreeStyle Libre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Armband
Description: Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Armband
Description: Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
Study: NCT04093908

Intervention type: OTHER
Intervention: Prediction of motor outcome after STN DBS based on preoperative variables
Description: Generating individual probabilities for motor response based on preoperative variables
Study: NCT03039361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine Assisted Psychotherapy
Description: Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
Study: NCT01821612

Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: PO

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine
Description: IV
Study: NCT04526392

Intervention type: OTHER
Intervention: Questionnaire
Description: Pubertal course questionnaire
Study: NCT01477502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual homeopathic treatment
Description: participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis

Intervention type: OTHER
Group type: OTHER
Intervention: standard treatment without homeopathy
Description: participants receive standard UTI prophylaxis
Study: NCT06234774

Intervention type: PROCEDURE
Intervention: Robot-assisted laparoscopic surgery

Intervention type: PROCEDURE
Intervention: Conventional (non-robotic) laparoscopic surgery
Study: NCT02772094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single arm, open-label
Description: Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ.
Study: NCT01173913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc001 10mg capsules
Description: Bi-daily administration. One cycle will last 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc003 10mg tablets and ModraDoc004 10/50 mg
Description: The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006 10 mg tablet
Description: Bi-daily administration. One cycle will last 7 days
Study: NCT03327714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion
Study: NCT01481870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib-sunitinib
Description: sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib-sorafenib
Description: sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
Study: NCT01435447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLu-Bu-Cy
Description: Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
Study: NCT01347125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImCardia Device
Description: The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
Study: NCT03762213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus GO VR HMD, application Happy Place (© Mimerse)
Description: The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: iPad, application Happy Place (© Mimerse)
Description: The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
Study: NCT03250052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (fimasartan or linagliptin) x 7days
Description: Part A: fimasartan, Part B: linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (fimasartan or linagliptin) x 7days
Description: Part A: fimasartan, Part B: linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (fimasartan and linagliptin) x 7days
Description: Part A \& Part B: Co-administration of fimasartan and linagliptin
Study: NCT00736918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management, Usual clinical practice and Providing paper based information for suicide prevention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual clinical practice and Providing paper based information for suicide prevention
Study: NCT00933959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Treatment as usual
Study: NCT05189314

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Surgical Resection of thyroid nodules

Intervention type: DEVICE
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation of thyroid nodules
Study: NCT03623620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Delivery of Mindfulness-Based Cognitive Therapy
Description: 12-week program that emphasizes mindfulness and cognitive behavioral skills
Study: NCT04385524

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adjuvanted Hepatitis B Vaccine
Description: Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
Study: NCT04684524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT03250052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (fimasartan and linagliptin) x 7days
Description: Part A \& Part B: Co-administration of fimasartan and linagliptin
Study: NCT01212991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Study: NCT02099175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Description: 1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients not needing ENI
Description: 1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed